AngioLab (XKRX:251280) Additional Paid-In Capital : ₩30,792.0 Mil(As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is AngioLab Additional Paid-In Capital?

AngioLab's quarterly additional paid-in capital stayed the same from Dec. 2021 (₩30,792.0 Mil) to Dec. 2022 (₩30,792.0 Mil) and stayed the same from Dec. 2022 (₩30,792.0 Mil) to Dec. 2023 (₩30,792.0 Mil).

AngioLab's annual additional paid-in capital stayed the same from Dec. 2021 (₩30,792.0 Mil) to Dec. 2022 (₩30,792.0 Mil) and stayed the same from Dec. 2022 (₩30,792.0 Mil) to Dec. 2023 (₩30,792.0 Mil).

AngioLab Additional Paid-In Capital Historical Data

The historical data trend for AngioLab's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AngioLab Additional Paid-In Capital Chart

AngioLab Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

8,313.52

25,581.45

30,791.96

AngioLab Semi-Annual Data
	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
Additional Paid-In Capital	Get a 7-Day Free Trial			8,313.52	25,581.45	30,791.96	30,791.96	30,791.96

AngioLab Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

AngioLab Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of AngioLab's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

AngioLab (XKRX:251280) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AngioLab Inc (XKRX:251280) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

65 Techno 3ro, Suite 159, Hanshin S Mecca, Yuseong-gu, Doejeon, CHN

Website

http://www.angiolab.co.kr

AngioLab Inc is a biotechnology company. It develops products based on angiogenesis inhibitors. It discovers, develops, and markets anti-angiogenic candidates to inhibit the abnormal growth of new blood vessel.

AngioLab (XKRX:251280) Headlines

No Headlines